JP2017526916A - 癌の診断 - Google Patents

癌の診断 Download PDF

Info

Publication number
JP2017526916A
JP2017526916A JP2017507713A JP2017507713A JP2017526916A JP 2017526916 A JP2017526916 A JP 2017526916A JP 2017507713 A JP2017507713 A JP 2017507713A JP 2017507713 A JP2017507713 A JP 2017507713A JP 2017526916 A JP2017526916 A JP 2017526916A
Authority
JP
Japan
Prior art keywords
cancer
sample
patient
oncoprotein
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017507713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526916A5 (enExample
Inventor
ツォン，チ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2017526916A publication Critical patent/JP2017526916A/ja
Publication of JP2017526916A5 publication Critical patent/JP2017526916A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G01N33/57575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017507713A 2014-08-13 2015-08-13 癌の診断 Withdrawn JP2017526916A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201404895X 2014-08-13
SG10201404895XA SG10201404895XA (en) 2014-08-13 2014-08-13 Diagnosis
PCT/SG2015/050259 WO2016024918A1 (en) 2014-08-13 2015-08-13 Diagnosis of cancer

Publications (2)

Publication Number Publication Date
JP2017526916A true JP2017526916A (ja) 2017-09-14
JP2017526916A5 JP2017526916A5 (enExample) 2018-09-13

Family

ID=55304429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507713A Withdrawn JP2017526916A (ja) 2014-08-13 2015-08-13 癌の診断

Country Status (6)

Country Link
US (1) US20170234880A1 (enExample)
EP (1) EP3189333A4 (enExample)
JP (1) JP2017526916A (enExample)
CN (1) CN106716132A (enExample)
SG (2) SG10201404895XA (enExample)
WO (1) WO2016024918A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022030626A1 (enExample) * 2020-08-06 2022-02-10

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075825A1 (en) * 2016-10-19 2018-04-26 Northwestern University Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
CN107058556A (zh) * 2017-05-09 2017-08-18 大连海事大学 一种用于评估硫丹促癌风险的方法
CN110669764B (zh) * 2017-12-11 2020-12-11 浙江大学 一种hsa-miR-10367 miRNA序列在抗肿瘤中的应用
CN110531082A (zh) * 2018-05-25 2019-12-03 国家纳米科学中心 用于乳腺癌检测及分子分型的外泌体检测装置和应用
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
CN118376789B (zh) * 2024-06-25 2024-09-13 南昌大学第一附属医院 一种用于诊断肺癌的检测试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091326A1 (en) * 2005-01-28 2006-08-31 Attogen Inc. Anti-prl-3 antibodies and methods of use thereof
JP2010530735A (ja) * 2007-05-03 2010-09-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体
JP2012508577A (ja) * 2008-11-12 2012-04-12 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 表現型を決定するためのエキソソームの使用方法およびそのシステム
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
SG10201903119QA (en) * 2011-09-06 2019-05-30 Agency Science Tech & Res Polypeptide vaccine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022030626A1 (enExample) * 2020-08-06 2022-02-10
WO2022030626A1 (ja) * 2020-08-06 2022-02-10 株式会社Ｌｓｉメディエンス 膀胱癌診断方法

Also Published As

Publication number Publication date
EP3189333A1 (en) 2017-07-12
US20170234880A1 (en) 2017-08-17
WO2016024918A1 (en) 2016-02-18
SG10201404895XA (en) 2016-03-30
SG11201701076TA (en) 2017-03-30
EP3189333A4 (en) 2018-04-18
CN106716132A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
US11219645B2 (en) Tumor infiltrating lymphocytes for treatment of cancer
JP2017526916A (ja) 癌の診断
US8871450B2 (en) Biomarker for colorectal cancer
JP2025029025A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法
ES2877757T3 (es) Tratamiento terapéutico de cáncer de mama basado en el estado de c-MAF
JP2018138058A (ja) 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
JP2018508183A (ja) 化学療法耐性癌を治療及び診断する組成物及び方法
JP7236164B2 (ja) 治療法に対する応答を予測する薬剤及び方法
JP6316498B2 (ja) Ｃｋａｐ４を標的分子とした抗腫瘍剤
JP2019517498A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
TW201620547A (zh) Ｐｄ－ｌ１陰性腫瘤之組合療法
JP2018516870A (ja) ３つの完全ヒトモノクローナル抗ｅｇｆｒ抗体の組み合わせを用いて上皮成長因子受容体（ｅｇｆｒ）の細胞外ドメインに変異を有する患者を治療する方法
JP2020040959A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
CN107531789B (zh) 用于抗血管新生和标靶癌症治疗的抗vegfr2人类抗体
JP2022519649A (ja) がんの診断および治療方法
CN103238069B (zh) 肺癌和结直肠癌中的bard1同工型及其应用
JP2014501918A (ja) ベバシズマブ併用療法のためのマーカーとしてのａｇｔｒ１
WO2022154037A1 (ja) がんの予後バイオマーカー
CA3112382A1 (en) Methods for treating pancreatitis
CN113677994B (zh) 用于评估t细胞功能和预测对疗法的应答的方法和药剂
CN111656194B (zh) Tnbc划分和治疗的方法和组合物
JP2025537128A (ja) 非小細胞肺癌の検出及び治療の方法
JP6341859B2 (ja) がんマーカーおよびその用途
WO2025075127A1 (ja) がんのバイオマーカー及び抗体治療
Hsu et al. Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN-ϒ reprograms tumor-associated macrophages to suppress triple negative breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180802

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190326